), the paraganglioma syndrome types 1–4 (PGL1–4), and the familial pheochromocytoma syndromes. Patients with hereditary pheochromocytoma have a lifelong risk of second paraganglial tumors and relapse and frequently have life-threatening, syndrome
Search Results
Birke Bausch, Ulrich Wellner, Dirk Bausch, Francesca Schiavi, Marta Barontini, Gabriela Sanso, Martin K Walz, Mariola Peczkowska, Georges Weryha, Patrizia Dall'Igna, Giovanni Cecchetto, Gianni Bisogno, Lars C Moeller, Detlef Bockenhauer, Attila Patocs, Karoly Rácz, Dmitry Zabolotnyi, Svetlana Yaremchuk, Iveta Dzivite-Krisane, Frederic Castinetti, David Taieb, Angelica Malinoc, Ernst von Dobschuetz, Jochen Roessler, Kurt W Schmid, Giuseppe Opocher, Charis Eng, and Hartmut P H Neumann
Yu Wang, Andres Roma, Rosalie Nolley, Fadi Abdul-Karim, Donna M Peehl, and Charis Eng
stage T2b–T2c tumors, PSA between 10 and 20 ng/ml, or Gleason score 7 ( D'Amico et al . 1998 b ). After radical prostatectomy (RP), 65–80% of patients with IRPC had 5-year relapse-free survival (RFS) ( D'Amico et al . 1998 b , c , d , Meng et al
A Faggiano, F Grimaldi, L Pezzullo, M G Chiofalo, C Caracò, N Mozzillo, G Angeletti, F Santeusanio, G Lombardi, A Colao, N Avenia, and P Ferolla
relapsing MTC. Patients and methods Patients Thirty-five consecutive MTC patients (17 males and 18 females, 32–82 years) were enrolled in this retrospective multicenter study after their informed consent had been obtained. A total thyroidectomy with central
Huy Gia Vuong, Toru Odate, Hanh T T Ngo, Thong Quang Pham, Thao T K Tran, Kunio Mochizuki, Tadao Nakazawa, Ryohei Katoh, and Tetsuo Kondo
HRAS being the most common genotype ( Goutas et al . 2008 , Moura et al . 2011 , Ciampi et al . 2013 , Lyra et al . 2014 ). RET mutation has been shown to be associated with an increased risk of tumor relapse and mortality ( Elisei et al
Sin-Ming Chow, Stephen Yau, Chung-Kong Kwan, Patricia C M Poon, and Stephen C K Law
et al. 2004 ). Apart from surgery, postoperative radioactive iodine (RAI) and external radiotherapy (EXT) can reduce LR relapse, especially in patients with postoperative LR residual disease ( Chow et al. 2002 c , Brierley et al. 2005
Giorgio Secreto, Paola Muti, Milena Sant, Elisabetta Meneghini, and Vittorio Krogh
of de novo or acquired resistance to anti-estrogens, that prevents about 50% of patients to benefit with the therapy ( Rechoum et al. 2014 , Fuji et al. 2014 , Ciupek et al . 2015 ) and occurrence of late relapse after anti-estrogens have been
Matthias S Dettmer, Anja Schmitt, Hans Steinert, David Capper, Holger Moch, Paul Komminoth, and Aurel Perren
, Sancisi et al . 2012 , Barbaro et al . 2014 ). One reason for this could be the fact that an adverse patient outcome with multiple tumor relapses and eventually death resulting from PTC is a rare event. As a matter of fact, only about 5% of PTCs will
H Yamashita, M Nishio, Y Ando, Z Zhang, M Hamaguchi, K Mita, S Kobayashi, Y Fujii, and H Iwase
with a positive expression of Stat5 had a significantly longer survival after relapse. Patients and methods Patients and breast cancer tissues Breast tumor specimens from 517 female patients with primary
Zhu Wang, Dinglan Wu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh, Shan Yu, Yuliang Wang, and Franky L Chan
comprehensive view on the expression profiles of NR superfamily in these in vitro and in vivo prostate cancer models. Our results identified some orphan NRs which exhibited common expression in both prostatospheroids and castration-relapse CRPC xenografts
Changmeng Cai and Steven P Balk
these agents due to mechanisms including increased expression of CYP17A1, with subsequent increases in de novo androgen synthesis being a potential mechanism for relapse. Conclusions Prostate expresses the enzymatic machinery for synthesis of
